Cargando…
CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa
Recessive dystrophic epidermolysis bullosa (RDEB) is an autosomal monogenic skin disease caused by mutations in COL7A1 gene and lack of functional type VII collagen (C7). Currently, there is no cure for RDEB, and most of the gene therapies under development have been designed as ex vivo strategies b...
Autores principales: | Wang, Xianqing, Wang, Xi, Li, Yinghao, A, Sigen, Qiu, Bei, Bushmalyova, Albina, He, Zhonglei, Wang, Wenxin, Lara-Sáez, Irene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630779/ https://www.ncbi.nlm.nih.gov/pubmed/38027067 http://dx.doi.org/10.1016/j.omtm.2023.101134 |
Ejemplares similares
-
Development of Minicircle Vectors Encoding COL7A1 Gene with Human Promoters for Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
por: Wang, Xianqing, et al.
Publicado: (2021) -
CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa
por: Webber, Beau R, et al.
Publicado: (2016) -
COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa
por: Hainzl, Stefan, et al.
Publicado: (2017) -
Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing
por: Bonafont, Jose, et al.
Publicado: (2019) -
Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing
por: Bonafont, Jose, et al.
Publicado: (2021)